skip to Main Content

Dr. O’Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib (ABT-888) in patients with pancreas adenocarcinoma (PDAC) harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Both study arms were initially considered to be experimental arms, says O’Reilly. Read more . . . 


Back To Top